Evidence map›Paper›PMID 30700761›Full record

ArticleScientific reports2019

Clonal dynamics monitoring during clinical evolution in chronic lymphocytic leukaemia.

Julia González-Rincón, Sagrario Gómez, Nerea Martinez, Kevin Troulé, Javier Perales-Patón, Sophia Derdak, Sergi Beltrán, Belén Fernández-Cuevas, Nuria Pérez-Sanz, Sara Nova-Gurumeta and 5 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. A genetic profiling guideline to support diagnosis and clinical management of lymphomas.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Guideline
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Julia González-RincónLymphoma Research Group, Medical Oncology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.
Sagrario GómezLymphoma Research Group, Medical Oncology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.
Nerea MartinezCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Kevin TrouléBioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Javier Perales-PatónBioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.ORCID 0000-0003-0780-6683
Sophia DerdakCNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Sergi BeltránCNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Belén Fernández-CuevasHematology Department, Hospital Universitario Puerta de Hierro-Majadahonda and Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.
Nuria Pérez-SanzHematology Department, Hospital Universitario Puerta de Hierro-Majadahonda and Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.
Sara Nova-GurumetaHematology Department, Hospital Universitario Puerta de Hierro-Majadahonda and Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.
Ivo GutCNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Fátima Al-ShahrourBioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Miguel A PirisCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
José A García-MarcoHematology Department, Hospital Universitario Puerta de Hierro-Majadahonda and Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain. jagarciam@aehh.org.
Margarita Sánchez-BeatoLymphoma Research Group, Medical Oncology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain. msbeato@idiphim.org.
Hospital Universitario Puerta de Hierro Majadahonda · ESInstituto de Investigación Sanitaria de Santiago · ESSpanish National Cancer Research Centre · ESUniversitat Pompeu Fabra · ESHospital Universitario Fundación Jiménez Díaz · ESInstituto de Investigación Marqués de Valdecilla · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic lymphocytic leukaemia is the most prevalent leukaemia in Western countries. It is an incurable disease characterized by a highly variable clinical course. Chronic lymphocytic leukaemia is an ideal model for studying clonal heterogeneity and dynamics during cancer progression, response to therapy and/or relapse because the disease usually develops over several years. Here we report an analysis by deep sequencing of sequential samples taken at different times from the affected organs of two patients with 12- and 7-year disease courses, respectively. One of the patients followed a linear pattern of clonal evolution, acquiring and selecting new mutations in response to salvage therapy and/or allogeneic transplantation, while the other suffered loss of cellular tumoral clones during progression and histological transformation.

Indexed as

Clonal EvolutionClone CellsExome SequencingFatal OutcomeGene FrequencyHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedMutagenesisMutation

Identifiers

PMID30700761
PMCPMC6353992
OpenAlexW2912553423

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.